Cell counters and viability systems

01Overview and value chain#

Markers EC: US FDA 21 CFR Part 11 + EU GMP Annex 11 for GxP cell-therapy and cell-line release testing | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)

Cell counters and viability systems automate what a manual hemocytometer count once did by hand: determining cell concentration and the live/dead fraction of a suspension, reported in seconds rather than the several minutes a trained technician needs per sample. Two detection principles dominate: image-based counting captures a bright-field or phase- contrast image of cells in a disposable slide or chamber and applies trypan-blue dye- exclusion image analysis to distinguish live from dead cells; fluorescence-based counting stains cells with a nucleic-acid dye and reads fluorescence intensity, extending the method to samples where dye exclusion alone is unreliable, such as highly viscous or debris-heavy suspensions. The instruments sit at every stage of a cell-culture workflow — a daily passage check in basic research, an in-process bioreactor sample during a monoclonal- antibody or cell-therapy run, and a release specification before a CAR-T or stem-cell product ships — and the shift from manual counting to automated systems has been driven largely by the reproducibility problem: operator-to-operator variation in manual hemocytometer counts commonly exceeds 20%, while an automated image-based system typically holds coefficient of variation under 10%.

The key directions of cell counting and viability analysis are:

1. Image-based dye-exclusion counting (Image-Based Counting): disposable-slide bright-field imaging with trypan-blue exclusion, the default replacement for manual hemocytometer counting in general cell-culture QC.
2. Fluorescence-based viability analysis (Fluorescence Viability): nucleic-acid dye staining read by fluorescence detection, extending accurate counting to viscous, pigmented or debris-heavy samples where dye exclusion alone is unreliable.
3. Closed-cassette and reagent-cartridge systems (Closed-System Counting): self- contained fluidic cassettes that minimize user contact with the sample, reducing contamination risk for GMP cell-therapy manufacturing environments.
4. In-line and at-line bioprocess counting (Bioprocess Counting): compact counters integrated into or adjacent to a bioreactor sampling line for frequent viable-cell- density monitoring during a production run.

Sectoral value chain#

[Cell sample] ──> [Sample loading: slide/cassette] ──> [Imaging or fluorescence detection] ──> [Concentration + viability result]
                                                                  │
                                                          (QC/release record)
                                                                  │
                                                                  ▼
[Culture-passage or release decision] <─── [Software: image analysis or fluorescence gating]

Value chain levels#

Cross-cutting technologies of the sector:

• AI-based cell segmentation: machine-learning image-segmentation models improve counting accuracy for clumped, aggregated or morphologically atypical cell populations compared to classical edge-detection algorithms.
• Disposable counting-slide standardization: pre-calibrated, single-use slides remove hemocytometer cleaning and chamber-depth calibration as sources of operator variability.
• Multi-parameter fluorescence panels: newer instruments add apoptosis, cell-cycle or GFP-expression channels alongside viability on the same fluorescence-detection platform.

02US#

The US market centers on bioprocess and cell-therapy manufacturing, where accurate viable- cell-density counting is a routine in-process control, plus a concentration of the category’s largest instrument brands.

bioprocess viable-cell-density monitoring, cell-therapy release counting, general cell-culture QC#

• Nexcelom (part of Revvity): the Cellometer line (Auto 2000, K2, Ascend) offers dual-fluorescence bright-field counting with built-in assays for specific cell types, used across academic, biotech and cell-therapy manufacturing labs.
• Beckman Coulter: the Vi-CELL BLU automates trypan-blue dye-exclusion counting with a 24-position sample carousel, reporting viability percentage, concentration and cell count for routine bioprocess and cell-culture QC.
• Thermo Fisher Scientific: the Invitrogen Countess 3 and Countess 3 FL automated cell counters provide rapid bright-field and fluorescence-based counting and viability analysis for general cell-culture workflows.

03CN#

Shanghai Ruiyu Biotech’s Countstar line is a confirmed China-headquartered instrument maker in this category — one of the few EQP-kind screens this session to clear with a domestic vendor rather than an import-only market.

domestic instrument origination, marketplace-distributed low-cost counters, growing biomanufacturing demand#

• Countstar (Shanghai Ruiyu Biotech): the Countstar automated cell counter and fluorescence cell analyzer line (including the Countstar Mira FL) is sold through Chinese biotech-equipment marketplaces and Western laboratory-equipment distributors, with the Mira FL fluorescence analyzer confirmed at retail through an independent US distributor.
• Screening note: evidence for this entity came primarily from marketplace listing titles rather than the vendor’s own product pages, so specification claims are kept general rather than citing exact performance numbers.

04EU#

Denmark’s ChemoMetec anchors Europe’s contribution with a closed-cassette design distinct from the open-slide approach common among US competitors.

closed-cassette fluidics, contamination-risk reduction for GMP environments, fluorescence-based viability#

• ChemoMetec (Denmark): the NucleoCounter line (NC-200, NC-203, NC-3000) and the newer XcytoMatic platform use a closed reagent-cassette design that limits user contact with the sample, positioned for consistent counting in regulated manufacturing environments.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack layers two detection physics — bright-field dye exclusion and fluorescence — on a common image-analysis or signal-processing software backbone, with cassette-based designs adding a contamination-control layer for regulated environments.

1. Trypan-blue dye-exclusion imaging:
   • Live cells with intact membranes exclude the trypan-blue dye and appear bright under bright-field imaging, while dead cells with compromised membranes take up the dye and appear dark.
   • Image-analysis software segments individual cells, applies the exclusion criterion per cell, and reports concentration and viability percentage typically in under a minute per sample.
2. Fluorescence-based nucleic-acid staining:
   • A cell-permeant or cell-impermeant fluorescent dye binds nucleic acids differentially based on membrane integrity, distinguishing live from dead cells by fluorescence intensity rather than optical dye exclusion.
   • Extends reliable counting to samples — pigmented, highly viscous, or debris-laden — where bright-field dye exclusion alone produces ambiguous results.
3. Closed-cassette fluidics:
   • A self-contained cassette pre-loads the counting chamber and reagent, minimizing direct user contact with the sample and the risk of cross-contamination between runs.
   • Suited to GMP cell-therapy manufacturing environments where documented, closed sample handling supports the broader aseptic-processing requirement.

07Value chains and production pipelines#

Industrial pipeline of a bioprocess viable-cell-density check (21 CFR Part 11 / EU GMP Annex 11)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Bioreactor sample pull  │ ───> │ 2. Staining & dilution     │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Image/signal analysis  │ <─── │ 3. Slide/cassette loading  │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Statistics & report    │ ───> │ 6. Passage/release decision│
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Bioreactor sample pull

A small-volume sample is drawn from the bioreactor or culture vessel through an aseptic sampling port, timed to the process schedule for viable-cell-density monitoring.

Stage 2: Staining and dilution

The sample is mixed with trypan blue or a fluorescent viability dye and diluted, if necessary, to bring the cell concentration within the instrument’s validated counting range.

Stage 3: Slide or cassette loading

The prepared sample is loaded into a disposable counting slide or a closed reagent cassette, depending on the instrument platform.

Stage 4: Image or signal analysis

Bright-field imaging with dye-exclusion analysis or fluorescence detection generates raw per-cell data, which segmentation software classifies as live or dead.

Stage 5: Statistics and report generation

Cell concentration, viability percentage and average cell diameter are calculated and logged, with GxP-validated systems generating a 21 CFR Part 11-compliant audit-trail record.

Stage 6: Passage or release decision

The result is compared against a culture-passage threshold for routine process control or against a validated release specification for a cell-therapy or cell-line product, driving the next-step decision.